Summary

Small Molecule Drug Discovery Outsourcing Market Summary

The global small molecule drug discovery outsourcing market size was estimated at USD 4.55 billion in 2024, and is projected to reach USD 10.62 billion by 2033, growing at a CAGR of 10.03% from 2025 to 2033. Rising research and development expenses, an increasing need for drug development, and a transition toward virtual pharmaceutical models drive the market.

Some other factors contributing to market growth are a rising number of registered studies, growing approval of small molecule drugs, advancements in medical technology, an upsurge in diseases under investigation, and the imperative for novel treatments. Currently, small molecule drugs have been the cornerstone of the pharmaceutical industry. These organic compounds, characterized by their low molecular weight, offer several advantages as therapeutic agents. These molecules provide advantages such as high oral bioavailability, adaptable dosing regimens, and the capability to engage intracellular pathways, making them applicable to a broad spectrum of diseases, particularly in areas like cancer, infections, and neurological disorders.

Besides, drug discovery plays a crucial role in developing these small molecule drugs, encompassing complex stages and cutting-edge technologies to formulate effective therapies and accelerate R&D pipelines. Thus, many pharmaceutical and biopharmaceutical companies are increasingly partnering with outsourcing companies specializing in the expertise to manage early discovery phases, including target identification, hit-to-lead processes, lead optimization, and the approval process. For instance, in 2024, the U.S. FDA Center for Drug Evaluation and Research approved 50 new molecular entities, consisting of 32 chemical entities & 18 biologic entities. Besides, of the NCEs, small molecules gained major attention and share, making up 91% (31 drugs), with the remaining drugs comprising peptides and nucleic acids.

Moreover, outsourcing in the pharmaceutical industry is gaining momentum as companies recognize the benefits of acquiring additional competencies essential for successful drug development and commercialization. Outsourcing provides specialized expertise, helps improve cash flow management, and offers significant manufacturing advantages, including reducing investment risks. Besides, developing costly in-house capabilities for early-stage technologies and products involves considerable risks throughout development. These factors have led to outsourcing as an emerging risk-averse alternative for product innovations. Moreover, companies often face challenges in determining the necessary scale for current and future product offerings or market penetration, complicating the design and scaling of in-house manufacturing. As a result, outsourcing has become a preferred option for product innovation.

Furthermore, innovative technologies, the rising prevalence of chronic and infectious diseases, and the growing need for new therapies support market growth. Advances such as artificial intelligence, machine learning, and high-throughput screening are streamlining the hit identification and lead optimization processes, supporting the market growth. Also, the advancement of precision medicine and AI-driven screening methods has further enhanced the efficiency of the discovery process. Similarly, advancements in drug design, predictive modeling, and precision medicine are enhancing the contributions of outsourcing partners in the early stages of drug discovery and development. Such factors are expected to drive the market growth over the estimated time period.

Global Small Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, end use, and region:

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Chemistry Services
• Biology Services
• Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory system
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology companies
• Academic Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Denmark
o Norway
• Asia Pacific
o Japan
o China
o India
o Thailand
o South Korea
o Australia
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o Argentina
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Workflow
1.2.2. Service
1.2.3. Therapeutics Area
1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Small Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising R&D costs in pharmaceutical/biopharmaceutical Industry
3.2.1.2. Increasing demand for outsourcing services in drug development
3.2.1.3. Technological advancements in drug discovery
3.2.1.4. Rising shortening time-to-market pressures
3.2.2. Market Restraint Analysis
3.2.2.1. Intellectual property (IP) and data security concerns
3.2.2.2. Limited standardization and reproducibility
3.2.2.3. Integration challenges with internal R&D pipelines
3.3. Clinical Trials Volume Analysis (2024)
3.3.1. Total Number Of Clinical Trials By Region
3.3.2. Total Number Of Clinical Trials, By Phase
3.3.3. Total Number Of Clinical Trials, By Study Design
3.3.4. Total Number Of Clinical Trials, By Key Therapeutic Area
3.4. Pricing Model Analysis
3.5. Technology Landscape
3.6. Market Analysis Tools
3.6.1. Porter’s Five Force Analysis
3.6.2. PESTEL by SWOT Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Small Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis
4.1. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
4.2. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
4.3. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
4.4. Target Identification & Screening
4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Target Validation & Functional Informatics
4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Lead Identification & Candidate Optimization
4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Preclinical Development
4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Small Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis
5.1. Small Molecule Drug Discovery Outsourcing Market, By Service: Segment Dashboard
5.2. Small Molecule Drug Discovery Outsourcing Market, By Service: Movement Analysis
5.3. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
5.4. Chemistry Services
5.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Biology Services
5.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Small Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis
6.1. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
6.2. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
6.3. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
6.4. Respiratory system
6.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Pain and Anesthesia
6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Oncology
6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Ophthalmology
6.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Hematology
6.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Cardiovascular
6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Endocrine
6.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Gastrointestinal
6.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.12. Immunomodulation
6.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.13. Anti-infective
6.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.14. Central Nervous System
6.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.15. Dermatology
6.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.16. Genitourinary System
6.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Small Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis
7.1. Small Molecule Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
7.2. Small Molecule Drug Discovery Outsourcing Market, By End Use: Movement Analysis
7.3. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
7.4. Pharmaceutical & Biotechnology companies
7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Academic Institutes
7.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Small Molecule Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2024 & 2033
8.3. North America
8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. U.S
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.4. Mexico
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4. Europe
8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.2. UK
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Germany
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.4. France
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.5. Italy
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.6. Spain
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Framework
8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Asia Pacific
8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. Japan
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Thailand
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. South Korea
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. Australia
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Latin America
8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. Argentina
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. MEA
8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Saudi Arabia
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.4. UAE
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.2. Company Market Share/Assessment Analysis, 2024
9.3. Company Profiles
9.3.1. WuXi AppTec
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Pharmaceutical Product Development, LLC
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Charles River Laboratories
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Laboratory Corporation of America Holdings (Covance)
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Eurofins
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Evotec
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Albany Molecular Research (Curia)
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. GenScript Biotech
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Pharmaron
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Syngene International
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Dalton Pharma Services
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Service Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Oncodesign
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Service Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Jubilant Biosys
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Service Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. Domainex
9.3.14.1. Company Overview
9.3.14.2. Financial Performance
9.3.14.3. Service Benchmarking
9.3.14.4. Strategic Initiatives
9.3.15. GenScript Biotech
9.3.15.1. Company Overview
9.3.15.2. Financial Performance
9.3.15.3. Service Benchmarking
9.3.15.4. Strategic Initiatives
9.3.16. Merck & Co., Inc.
9.3.16.1. Company Overview
9.3.16.2. Financial Performance
9.3.16.3. Service Benchmarking
9.3.16.4. Strategic Initiatives
9.3.17. QIAGEN
9.3.17.1. Company Overview
9.3.17.2. Financial Performance
9.3.17.3. Service Benchmarking
9.3.17.4. Strategic Initiatives
9.3.18. Dr. Reddy Laboratories Ltd.
9.3.18.1. Company Overview
9.3.18.2. Financial Performance
9.3.18.3. Service Benchmarking
9.3.18.4. Strategic Initiatives
9.3.19. Pharmaron Beijing Co., Ltd.
9.3.19.1. Company Overview
9.3.19.2. Financial Performance
9.3.19.3. Service Benchmarking
9.3.19.4. Strategic Initiatives
9.3.20. TCG Lifesciences Pvt Ltd.
9.3.20.1. Company Overview
9.3.20.2. Financial Performance
9.3.20.3. Service Benchmarking
9.3.20.4. Strategic Initiatives
Chapter 9 Key Recommendations